Several studies have shown that treatment of xenograft cancer models with inhibitors of VEGF-A or VEGFRs increases T cell recruitment and infiltration into tumors [90,91,92] and can exert a synergistic antitumor effect with anti-PD1 therapy [93]. Here, PDCD1 is linked to cancer.